News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
8,628 Results
Type
Article (1357)
Company Profile (4)
Press Release (7267)
Section
Business (3542)
Career Advice (10)
Deals (483)
Drug Delivery (4)
Drug Development (1671)
Employer Resources (4)
FDA (263)
Job Trends (295)
News (5894)
Policy (541)
Tag
2024 Biotech Beach Standard (1)
Academia (20)
Adcomms (3)
Allergies (1)
Alliances (1027)
ALS (2)
Alzheimer's disease (9)
Antibody-drug conjugate (ADC) (11)
Approvals (257)
Artificial intelligence (6)
Autoimmune disease (3)
Bankruptcy (5)
Best Places to Work (152)
BIOSECURE Act (1)
Biotechnology (2)
Breast cancer (3)
Cancer (40)
Cardiovascular disease (6)
Career advice (10)
Cell therapy (3)
Clinical research (1370)
Collaboration (15)
Compensation (1)
COVID-19 (115)
CRISPR (2)
C-suite (8)
Data (20)
Denatured (2)
Diabetes (1)
Diagnostics (26)
Diversity, equity & inclusion (2)
Drug discovery (1)
Drug pricing (4)
Duchenne muscular dystrophy (2)
Earnings (1014)
Editorial (3)
Employer branding (2)
Employer resources (4)
Events (705)
Executive appointments (28)
FDA (269)
Featured Employer (1)
Frontotemporal dementia (1)
Funding (9)
Gene editing (3)
Gene therapy (2)
GLP-1 (15)
Government (69)
Healthcare (187)
Immunology and inflammation (11)
Infectious disease (146)
Inflammatory bowel disease (2)
Inflation Reduction Act (1)
Intellectual property (1)
IPO (131)
IRA (2)
Job creations (146)
Job search strategy (9)
Labor market (1)
Layoffs (23)
Leadership (1)
Legal (149)
Liver cancer (1)
Lung cancer (7)
Management (1)
Manufacturing (5)
Medical device (16)
Medtech (16)
Mergers & acquisitions (354)
Metabolic disorders (8)
Neurodegenerative disease (3)
Neuropsychiatric disorders (1)
Neuroscience (16)
NextGen: Class of 2025 (77)
Non-profit (31)
Northern California (26)
Obesity (6)
Opinion (12)
Ovarian cancer (4)
Pain (1)
Pancreatic cancer (1)
Parkinson's disease (1)
Patents (12)
People (1303)
Pharmaceutical (2)
Phase I (353)
Phase II (552)
Phase III (563)
Pipeline (32)
Podcasts (11)
Policy (6)
Postmarket research (97)
Preclinical (103)
Prostate cancer (1)
Psychedelics (1)
Radiopharmaceuticals (4)
Rare diseases (9)
Real estate (76)
Regulatory (367)
Reports (2)
Research institute (27)
Resumes & cover letters (1)
RNA editing (1)
RSV (23)
Series A (3)
Series B (1)
Sickle cell disease (2)
Southern California (19)
Special edition (3)
Spinal muscular atrophy (11)
Sponsored (1)
Startups (104)
Stomach cancer (3)
Supply chain (2)
The Weekly (8)
United States (204)
Vaccines (89)
Venture capitalists (3)
Weight loss (5)
Date
Today (2)
Last 7 days (5)
Last 30 days (26)
Last 365 days (506)
2025 (124)
2024 (497)
2023 (532)
2022 (727)
2021 (607)
2020 (516)
2019 (409)
2018 (331)
2017 (401)
2016 (429)
2015 (658)
2014 (462)
2013 (384)
2012 (337)
2011 (394)
2010 (385)
Location
Africa (36)
Asia (563)
Australia (171)
California (63)
Canada (21)
China (15)
Colorado (1)
Connecticut (2)
Europe (3115)
Florida (1)
Georgia (1)
Illinois (10)
Indiana (3)
Japan (3)
Maryland (2)
Massachusetts (54)
New Hampshire (2)
New Jersey (24)
New York (7)
North Carolina (7)
Northern California (26)
Pennsylvania (13)
South America (22)
Southern California (19)
Texas (15)
Utah (2)
Virginia (1)
Washington D.C. (3)
Washington State (6)
Wisconsin (1)
8,628 Results for "gsk".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Vaccines
GSK Builds on Real-World Experiment to Study Shingrix’s Impact on Dementia
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” experiment to determine whether 65- and 66-year-olds who received GSK’s shingles vaccine Shingrix have reduced dementia risk.
March 25, 2025
·
1 min read
·
Dan Samorodnitsky
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and ViiV will push forward with their long-acting antivirals after touting positive early-stage results.
March 12, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
January 13, 2025
·
2 min read
·
Tristan Manalac
Vaccines
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.
January 8, 2025
·
2 min read
·
Tristan Manalac
Ovarian cancer
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in First-Line Ovarian Cancer
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the third quarter.
December 20, 2024
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
GSK Strikes Third Agreement This Week, Leans Further Into Neuro
The Muna partnership will give GSK access to Muna’s MiND-MAP platform, which it will apply to postmortem brain samples to identify potential therapeutic targets for Alzheimer’s disease.
December 5, 2024
·
2 min read
·
Tristan Manalac
Policy
GSK Quits Trade Group BIO as Industry Faces Uncertain Political Future
GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug price negotiation program.
November 11, 2024
·
2 min read
·
Tristan Manalac
Cancer
GSK Touts 42% Survival Benefit for Blenrep in Multiple Myeloma, Strengthening Bid for Market Return
The overall survival edge over J&J’s Darzalex will help GSK strengthen its case as it plots the market comeback of Blenrep, which was pulled after a failed confirmatory study.
December 10, 2024
·
2 min read
·
Tristan Manalac
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
One year after a potential $1.7 billion deal with Hansoh Pharma, GSK goes back to China to forge another alliance with DualityBio for another deal that could be worth up to $1 billion as it continues to build up its ADC portfolio.
December 4, 2024
·
1 min read
·
Kate Goodwin
Cancer
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster potential for the antibody-drug conjugate.
November 14, 2024
·
2 min read
·
Tristan Manalac
1 of 863
Next
